Latest From Nikon Corp.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.
AstraZeneca took on a large respiratory portfolio through a $700 million deal with Actavis; Pfizer improved biosimilar capabilities through its $17 billion takeover of Hospira. Follow-on public offerings dominated biopharma and device financing.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced February-March 2015.
- Medical Devices
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Nikon Corp.
- Senior Management
- Junichi Itoh, Pres.
- Contact Info
Phone: (81) 3-6433-3600
2-15-3 Shinagawa Intercity Tower C
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.